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Abstract
Individuals with osteoarthritis (OA) are at greater risk of cardiovascular and
cerebrovascular incidents; yet, cerebrovascular control remains uncharacterized. Our primary outcome was to acquire cerebrovascular control metrics in
patients with OA and compare measures to healthy control adults (CTL)
without OA or cardiovascular complications. Our primary covariate was a 10year risk factor for cardiovascular and stroke incidents, and secondary covariates were other cardiovascular disease risk factors (i.e., body mass index, carotid intima media thickness, and brachial flow-mediated dilation). Our
secondary outcomes were to assess anatomical and functional changes that
may be related to cerebrovascular reactivity were also acquired such as white
matter lesion volume and brief cognitive assessments. In 25 adults (n = 13
CTL, n = 12 OA), under hypercapnia, magnetic resonance imaging (3T) was
used to acquire a “Global Cerebrovascular Reactivity” index across the larger
intracranial cerebral arteries and white matter lesions, and transcranial
Doppler was used for both middle cerebral artery hemodynamic responses to
hypercapnia and to assess autoregulation via a sit-to-stand task. Compared
to CTL, OA had lower “Global Cerebrovascular Reactivity” index responses to
hypercapnia, autoregulatory responses, and greater white matter lesions
(P < 0.05). These differences persisted after covarying for the outlined primary
and secondary covariates. Patients with OA, in the absence of known cardiovascular disease, can exhibit pre-clinical and impaired (compared to CTL)
peripheral and cerebrovascular control metrics.
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Introduction
All-cause mortality in people with osteoarthritis (OA) is
related to cardiovascular disease (CVD) (Calvet et al.
2016; Hall et al. 2016; Veronese et al. 2016), and a greater
risk of cerebrovascular disease such as stroke (Hsu et al.
2017). Osteoarthritis shares several disease characteristics
with CVD and cerebrovascular disease: hypertension
(Veronese et al. 2017), arterial intima media thickening
(IMT) (Hoeven et al. 2013), and endothelial dysfunction
(via flow-mediated dilation; FMD) (Alkatan et al. 2016).
Osteoarthritis often includes chronic low-grade inflammation, both locally at the involved joint(s) and systemically
(summarized in a recent review (Al-Khazraji et al. 2018)).
Importantly, systemic inflammation negatively impacts
cerebrovascular health via disrupted blood–brain barrier
(Kuhlmann et al. 2009; Hsuchou et al. 2012), cerebral
small vessel disease (Pantoni, 2010), and stroke (Rost
et al. 2001; Patgiri et al. 2014; Yu et al. 2017). Such cerebrovascular dysfunctions can, in part, lead to long-term
neural or functional damage as seen with cerebral
microvascular damage indicated by white matter lesions
and/or play a role in cognitive impairment (McKetton
et al. 2019). Causal studies are unavailable, yet prevalence
of dementia remains greater in people with OA compared
to those without OA (Weber et al. 2019). This includes
vascular-related dementia, whose underlying neuropathology is caused by dysfunctional cerebrovasculature (Raz
et al. 2016). Despite shared risk factors with cerebrovascular disease, presence of chronic inflammation, and potential risk of cerebrovascular impairment, cerebrovascular
physiology remains unstudied in OA.
Cerebrovascular function generally is characterized by:
cerebrovascular reactivity (to vasoreactive stimuli such as
carbon dioxide; CO2) and cerebral autoregulation (cerebral
blood flow maintenance in the face of systemic blood pressure fluctuations). Cerebrovascular reactivity is impaired
in patients with acute ischemic stroke (Salinet et al. 2015),
and in patients with cerebral small vessel disease suffering
from lacunar strokes (Deplanque et al. 2013). Autoregulation indices predicted Glasgow Outcome Scale in a sample
of patients after traumatic brain injury (Rivera-Lara et al.
2017), impaired autoregulation is associated with brain
atrophy and worse long-term functional status in older
adults with ischemic stroke (Aoi et al. 2012). Although
cerebrovascular disease risk factors are expressed by
patients with OA, there is a paucity of research that quantifies cerebrovascular control in such patients.
Therefore, the purpose of this study was to use ultrasound and magnetic resonance imaging (MRI) modalities
to explore cerebrovascular control in individuals with knee
OA, yet without known cardiovascular/cerebrovascular
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disease. This study was exploratory in nature and is the
first to assess cerebrovascular physiology in a convenience
sample of individuals with OA who otherwise have not
experienced vascular-related incidences.

Methods
Overall study design
For our primary objective, we combined hemodynamic,
ultrasound imaging, and magnetic resonance imaging data
to assess cerebrovascular control, operationally defined
by: (1) middle cerebral artery (MCA) flow reactivity in
response to hypercapnia (elevated levels of end-tidal
CO2), (2) an index of averaged cerebrovascular reactivity
in larger intracranial arteries, referred to as “Global Cerebrovascular Reactivity”, and (3) an index of MCA
dynamic cerebral autoregulation in response to a stepwise reduction in mean arterial pressure (i.e., sitting to
standing positions), referred to as Rate of Regulation
(RoR). We focused on hemodynamics, flow reactivity and
autoregulation in the MCA as it is easily accessible and is
the most common site for cerebral infarction (Hedna
et al. 2013). We then assessed the meta-variables that
were used to calculate “Global Cerebrovascular Reactivity,” which included comparing reactivity of nine
intracranial vessels between the two groups.
In cardiac patients that exhibit several of the CVD risk
factors that are generally found in people living with OA
(Hoeven et al. 2013; Alkatan et al. 2016; Veronese et al.
2017), cerebrovascular reactivity and global cognitive
scores are reduced in brain regions associated with cognition (Anazodo et al. 2015). For our secondary objective,
we explored: (1) between-group brain anatomical differences such as whole brain, gray and white matter volumes
as blood flow changes may accommodate brain volumes,
(2) early signs of small vessel damage indicated by white
matter lesions, and (3) modest insight on cognitive capacity, via brief cognitive assessments, as there may be a link
between cerebrovascular health and cognition.
Cerebrovascular outcomes related to OA are difficult to
study independent of other co-existing conditions; as
such, primary analyses included comparing cerebrovascular function between those with and without OA while
covarying for the 10-year risk rate for CVD and stroke
(Kim et al. 2016). The 10-year risk rate for CVD and
stroke is calculated by processing an individual’s various
identified risk factors (e.g., age, sex, cholesterol, high-density lipoprotein, systolic blood pressure (SBP), smoking
history, diabetes mellitus) into a single composite value
where a greater value indicates greater risk of CVD or
stroke onset. Our secondary covariates included other risk
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factors which are not used to calculate the 10-year risk
score and were included as independent covariates in our
analyses: body mass index (BMI), IMT, and FMD. The
SBP was also accounted as an independent covariate as a
means of sensitivity analysis, despite being included in the
10-year risk score, as it is a predominant risk for white
matter lesions and other cerebrovascular pathology.
For our secondary analyses, we compared the metavariables (i.e., individual vascular reactivity across nine
intracranial vessels) that make up the “Global Cerebrovascular Reactivity” variable, between individuals with and
without OA while covarying for our primary covariate.
We also looked at between-group differences of white
matter lesions and brief cognitive assessments while
accounting for the primary covariate.

Eligibility criteria
We recruited a convenience sample of 12 patients previously diagnosed with knee OA, who had no known history of CVD, were 40–75 years of age and were not using
anti-inflammatory medication. All patients had symptomatic and radiographic knee OA confirmed by their
primary care physician (Altman et al. 1986). We also
recruited 13 healthy controls (CTL) with no knee symptoms and no known history of arthritis (e.g., osteoarthritis, rheumatoid, gout, etc.), or CVD. Participants were
excluded if they were smokers, pregnant, or had any of
the following conditions: Raynaud’s disease, respiratory
illnesses, diabetes, claustrophobia, history of psychosis,
eating disorders, manic or bipolar disorder, major psychiatric conditions, or dependence on alcohol or drugs. All
participants provided written informed consent and were
excluded if they were unable to provide written informed
consent, or complete forms due to language or cognitive
difficulties. The Human Subjects Research Ethics Board at
the University of Western Ontario (London, Ontario,
Canada) approved the experiment protocols herein.

Anthropometrics, blood work, cognitive
tests, and risk scores
Testing occurred over two sessions (each completed by
12 PM) separated by one to 30 days that involved a laboratory session and a neuroimaging session. All participants refrained from exercise, alcohol, non-steroidal antiinflammatory drugs, and caffeine 12 h prior to all testing,
and fasted 8 h for the blood sample.
Age, height, and weight were collected. The fasted blood
plasma was analyzed for lipids, glucose, insulin, high-sensitivity C-reactive protein (hs-CRP), and glycated hemoglobin (HbA1c) levels. Participants completed a health history
form and two cognitive assessments: (1) the Montreal
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Cognitive Assessment (MoCA), a screening test for mild
cognitive impairment (Nasreddine et al. 2005), and (2) the
Trail Making Test (TMT) A and B, a neuropsychological
assessment of speed of processing, mental flexibility, and
executive functioning (Tombaugh 2004).

Hemodynamics and cerebrovascular
reactivity of the MCA
While supine, 5 min baseline data were collected which
included continuous beat-by-beat mean arterial pressure
(MAP), heart rate, end-tidal partial pressure of carbon
dioxide (PETCO2), and MCA blood velocity. After 5 min
of breathing room air, participants breathed a gas mixture
with elevated CO2 levels (5% CO2, 95% O2) using a 5L
Douglas bag and a ventilation tube attached to the bottom of the face mask, and then 3 min of recovery while
breathing room air. Using transcranial Doppler, the MCA
was insonated with a 2-MHz ultrasound probe placed at
the temporal window and peak blood flow velocity envelope was collected using the Neurovision TCD System
(Multigon Industries Inc., NY). Continuous beat-to-beat
arterial blood pressure was monitored using a Finapres
Finometer system, where a finger cuff was placed on the
middle phalange of the third finger, and the finger blood
pressure was calibrated with an upper arm cuff
(Finapres Medical Systems, Amsterdam, Netherlands).To
assess pressure-independent changes in MCA velocity, a
surrogate for vascular conductance was measured as the
quotient between MCA velocity and corresponding mean
arterial pressure (MAP). All devices were connected to a
PowerLab data acquisition system (ADInstruments, Dunedin, Otago, New Zealand) and saved for offline analysis
using LabChart software (LabChart Pro v.8, ADInstruments, Dunedin, Otago, New Zealand).

Cerebrovascular autoregulation in MCA
using a sit-to-stand protocol
The sit-to-stand protocol elicits a rapid but transient
reduction in systemic blood pressure leading to concurrent changes in MCA blood flow, enabling the opportunity to study compensatory myogenic cerebrovascular
responses (Sorond et al. 2009). To begin, participants sat
upright, and without a back support. After 3 min of baseline data acquisition, participants stood unassisted for
3 min before resuming the seated position. Three sit-to-stand tasks were completed, and a minimum 10 mmHg
drop in mean arterial pressure MAP was considered
acceptable. Rate of regulation (RoR) was calculated using
the method described by Aaslid et al. (1989) and Labrecque et al. (2019), described in brief as calculating the
ratio between the normalized slope of cerebrovascular
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resistance (to the MCA blood velocity nadir time point)
to the corresponding normalized drop in mean arterial
pressure (Aaslid et al. 1989).

Magnetic resonance imaging (MRI) of
cerebrovascular responses and brain
anatomy
All imaging was conducted on a 3.0 T MRI (Prisma Fit,
Siemens, Erlangen, Germany) using a 32-channel head
coil. An MRI-compatible respiratory plethysmography
belt was used for breathing rate tracking, and a face mask
for PETCO2 measurement. Imaging details are below.

imaging). A 5-inch wide Hokanson cuff was placed 5 cm
distal to the antecubital fossa and attached to a Hokanson
rapid cuff inflator (E20 Rapid Cuff Inflator, Hokanson,
D. E. Hokanson Inc., Bellevue, WA). The ultrasound
probe position was fixed to ensure stable imaging at an
insonation angle of 60°. The FMD protocol included a 1min baseline (brachial diameter images captured within
1 min before inflation), followed by a 5-min cuff inflation
(200 mmHg), and 3 min of recovery. Brachial artery
diameter images were captured at 15, 30, 45, 50, 55,
60 sec of the first minute, 5, 10, 15, 30, 45, 60 sec in the
second minute, and at 15, 30, 45, and 60 sec in the third
minute (Coverdale et al. 2017). Continuous spectral mean
flow velocity signal was measured throughout.

Large cerebral artery reactivity
A T1-weighted anatomical scan was obtained prior to, and
during a hypercapnic stimulus (5% CO2, 95% O2). The
hypercapnia image was initiated 2 min following initiation
of the hypercapnia to capture steady state conditions (Coverdale et al. 2014). The T1-weighted 3D SPACE pulse
sequence used a radial trajectory, producing black-blood
with little flow artifact, improving signal contrast between
vessel lumen and tissue. High-resolution images (0.72 mm
isotropic, whole brain) were acquired in the sagittal orientation (TE = 11.0 msec, TR = 700 msec, FOV = 230 mm,
BW = 625Hz/px, iPat = 3, TA = 5:28 min).
Primary covariate: 10-year risk rate for CVD/stroke
index
The 10-year risk of heart disease or stroke index was calculated using the algorithm presented by American College
of Cardiology/American Heart Association Task Force
(Goff et al. 2013). For example, the 10-year risk for 55year-old, nonsmoker without diabetes, a total cholesterol
level of 213 mg/dL, high-density lipoprotein cholesterol
level of 50 mg/dL, and untreated systolic BP of 120 mmHg
will result in a predicted risk factor value of 2.1% for white
women, and 5.3% for white men (Goff et al. 2013).
Secondary covariates: BMI, IMT, FMD, and SBP
The BMI and SBP were collected anthropometric and
baseline hemodynamic recordings.
Right carotid artery IMT was measured using B-mode
ultrasound imaging (GE Vivid 7, 10 MHz), and all diameters and IMT were measured offline using EchoPAC
software (GE Healthcar).
The FMD protocol was conducted in the right brachial
artery. While supine, the right brachial artery was imaged
using duplex ultrasonography (GE Vivid 7, 10 MHz
imaging transducer; 4.7 MHz Doppler ultrasound
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Whole brain volume
A 3DT1 scan was performed for full brain volume analysis. The following imaging parameters were used:
TE = 2.98 msec,
TR = 2300 msec,
FOV = 256 mm,
BW = 240 Hz/px, iPat = 2, TA = 5:21 min.
White matter hyperintensities
A fluid-attenuated inversion recovery (FLAIR) scan was
acquired for analysis of white matter hyperintensity volumes (TE = 387 msec, TR = 5000 msec, FOV = 230 mm,
BW = 751 Hz/px, iPat = 2, TA = 5:42 min).

MRI analysis
Cross-sectional area (CSA) of the basal cerebral conduit
vessels were measured from T1-weighted scans using multiplanar reconstruction in OsiriX software (Pixmeo©, Bernex, Switzerland). Measures included bilateral (L-left, Rright) subcranial internal carotid (LICA and RICA) arteries, and the major arteries in the circle of Willis including
the basilar (BA), bilateral posterior cerebral (LPCA and
RPCA), middle cerebral (LMCA and RMCA), and anterior
cerebral (LACA and RACA) arteries during baseline and
elevated CO2 T1 scans. In the coronal plane, cross-hairs
were positioned parallel to the longitudinal slice of the
artery, and a blinded trained observer measured CSAs.
Cerebrovascular reactivity across the basal conduit arteries
was measured as the percent change in CSA divided by the
change in PETCO2 during hypercapnia. Similarly, the
MCA cerebrovascular flow reactivity (%/mmHg) was measured as percent change in calculated flow (from baseline)
divided by the change in PETCO2 during hypercapnia. To
provide an overall characteristic of cerebrovascular reactivity between groups, “Global Cerebrovascular Reactivity”
index was calculated as the average of cross-sectional reactivity responses across the nine intracranial vessels.
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Brain images were evaluated for white and gray matter
volume, and white matter hyperintensities were assessed
for measures of white matter lesions. Whole brain volume
(without ventricles), white and gray matter volume, and
white matter hyperintensity lesions were obtained from
3DT1 images. Brain volumes were determined using the
FreeSurfer software, version 5.3.0 (http://surfer.-nmr.mgh.
harvard.edu/).
Based on Schmidt et al. (2012), white matter hyperintensity lesions were segmented using the lesion growth
algorithm from the Lesion Segmentation Toolbox (www.
statistical-modelling.de/lst.html) for Statistical Parametric
Mapping software (SPM12, http://fil.ion.ucl.ac.uk/spm). A
pre-determined initial threshold (j = 0.30) was used to
obtain binary lesion maps. Lesion volumes (mm3) were
summed within an individual and reported as group
averages.

Statistical analyses
All statistical analyses were conducted using IBM SPSS
Statistics software (v.25; IBM Corp., Armonk, NY). Univariate general linear model (GLM) analyses were conducted to assess between-group differences for all
measured and calculated experimental variables. Primary
or secondary covariate analyses were conducted depending
on the variable of interest: (1) cerebrovascular control metrics were assessed between groups while covarying for primary and secondary covariates, (2) between-group
individual vessel reactivity across the nine intracranial large
cerebral arteries that make up the Global Cerebrovascular
Reactivity index were analyzed using GLM and the primary
covariate, and (3) brain volumes, white matter lesions, and
cognitive assessments were compared using a GLM; and
white matter lesions and cognitive assessments were covaried for the primary covariate but also for SBP as it is a
strong factor in development of lesions. Where differences
existed, cognitive assessments were covaried for white matter lesion volume. An alpha-level of P < 0.05 was selected,
and effect sizes are reported as eta squared values (g2),
where a large effect size was accepted when g2 > 0.14.
Where possible, between-group mean differences and 95%
confidence intervals were calculated, with unadjusted and
adjusted means provided in tables.

Results

Cerebrovascular Control in Osteoarthritis

Glucose, cholesterol, high-density lipoprotein (HDL),
low-density lipoprotein (LDL), HBA1C, high-sensitivity
C-reactive protein (hsCRP), and insulin were similar
across groups. Compared to the CTL group, those with
OA had higher triglycerides (Table 1).
The PETCO2, MAP, MCA blood velocities, and MCA
vascular conductance were similar between groups at
baseline and during hypercapnia (Table 1).

Primary and secondary covariates
The 10-year risk score for CVD/stroke was greater in
those OA than in CTL (Table 2). Carotid IMT was
greater in OA than in CTL, while brachial artery FMD
was lower in OA than in CTL (Table 2).

Cerebrovascular control: MCA blood flow
reactivity, global cerebrovascular reactivity,
and autoregulation
Between groups, baseline cross-sectional areas were similar across the nine intracranial large cerebral arteries
(Fig. 1). Individual vessel reactivities were different
between the groups; specifically, RMCA, LACA, RACA,
and basilar CSA reactivity were lower in the OA group
compared with CTL (Fig. 1).
The resting (pre-CO2) MCA calculated blood flows
were 225  50 mL/min versus 233  69 mL/min (CTL
vs. OA; mean  SD) with a P-value of 0.78, indicating
baseline MCA calculated blood flow values were similar
between groups. The MCA Blood Flow Reactivity, Global
Cerebrovascular Reactivity (averaged over 9 vessels/individual) and RoR were greater in the CTL group than in
the OA group even after accounting for primary and secondary covariates (Fig. 2 and Table 3).

Cerebral anatomy and cognitive
assessments
Total brain volumes (without ventricles), and white and
gray matter volumes were similar across groups, while
white matter lesions were greater in OA than in CTL
(Table 4). Compared to CTL, OA had lower MoCA
scores, that remained different between the groups after
primary covariate analysis but not after covarying for
white matter lesion volumes (Table 4). The TMT A and B
times were similar between groups (Table 4).

Participant characteristics, blood analysis,
and hemodynamics

Discussion

The CTL and OA groups were of similar age. The BMI
and SBP measurements were greater in OA, and diastolic
blood pressures were similar between groups (Table 1).

To the best of our knowledge, this is the first study to
investigate cerebrovascular control in patients with OA.
The main and summarized finding was that these patients
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Univariate general linear model (GLM) comparing values between control (CTL), and those with osteoarthritis (OA). Between-group mean differences (MD) with 95% confidence intervals (CI;
upper, lower bounds) and values in mean  SD are provided. MAP and PETCO2 are in mmHg, MCA conductance in cm/s/mmHg, and MCA velocity in cm/s. BL, baseline; HC, hypercapnia.
Bolded P-values indicate significance (P < 0.05).
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30  6
139  12
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57  12
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Characteristics
n; males/females
Age (y)
BMI (kg/m2)
Seated SBP (mmHg)
Seated DBP (mmHg)
Blood analysis
Glucose (mmol/L)
Cholesterol (mmol/L)
HDL (mmol/L)
LDL (mmol/L)
Triglycerides (mmol/L)
HbA1C (%)
hsCRP (mg/mL)
Insulin (pmol/L)

PETCO2 and Hemodynamics
g2
P-value
MD (95% CI)
OA
CTL

Table 1. Participant characteristics, blood analysis, and hemodynamic measurements during hypercapnia.

CTL

43
48
96
104
54
63
0.58
0.63

OA

6
5
15
17
8
15
0.18
0.20

MD (95% CI)

P-value

g2
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expressed impairments in carbon dioxide-induced dilatory
and autoregulatory function compared to healthy controls, which persisted after statistically controlling for
major co-existing vascular disease risk factors. Therefore,
these preliminary data point to an important and previously undetected cerebrovascular impairment in participants with knee OA. Importantly, these patients are not
routinely screened for cerebrovascular impairments
despite higher risk of for stroke. In these regards, the data
provide scientific rationale for pursuing future work in
this area of study.
The current group of participants with OA exhibited
impaired peripheral vascular health, as well as dysfunctional cerebrovascular reactivity, autoregulatory capacity,
and greater white matter lesion volumes, compared to
healthy controls. Participants with OA were irregular consumers of medications, and otherwise undiagnosed with
any vascular or neurological concerns. These data suggest
an association between established OA and subclinical
impairments in cerebrovascular control; however, we cannot conclude that our findings relate to or imply dysfunctions in cerebrovascular health. Our participants did not
report symptoms of established cerebrovascular dysfunction (e.g., cerebrovascular disease, pre-syncope symptoms). Whether our findings provide insight on future
outcomes or progression of underlying subclinical impairments is not within the boundaries of this study. Such
links require future studies that target longitudinal evaluation of cerebrovascular health outcomes in individuals
with OA.
Abnormal peripheral vascular metrics, such as greater
carotid intima media thickness (Hoeven et al. 2013) and
decreased flow-mediated dilation (Alkatan et al. 2016) are
reported in OA. The current study supports these earlier
reports. However, the current observations of progressive
cerebrovascular dysfunction are novel in this patient
group. “Global cerebrovascular reactivity” was calculated
as an index for average cerebrovascular reactivity within
the larger intracranial cerebral arteries. Since cerebrovascular reactivity was calculated as percent changes in crosssectional area during hypercapnia from baseline levels, we
have accounted for inter-vascular differences in baseline
vascular dimensions. Therefore, this metric provides a
global account for cerebrovascular reactivity and accommodates the anatomical and functional layout of the cerebrovascular network (Devault et al. 2008). Global
reactivity was lower in the OA group, even after adjusting
for the 10-year CVD/stroke risk factor and other vascular
disease risk factors. As a point of interest and further
investigation, between-group differences in individual vessel reactivity was present even after adjusting for the 10year CVD/stroke risk factor. These findings suggest that
cerebrovascular impairment in the OA group occurred
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Table 2. Primary and secondary covariates used in primary and secondary analyses of cerebrovascular control variables.
Covariate
Number
Primary covariate
10-year risk factor for CVD/stroke
Secondary covariates
BMI (kg/m2)
FMD (%)
IMT (mm)
SBP (mmHg)

1
2
3
4
5

CTL

OA

6  6 (n = 13)

11  5 (n = 12)

26
9.5
0.43
126






2 (n = 13)
4.3 (n = 13)
0.05 (n = 13)
11 (n = 13)

30
3.7
0.55
139






6 (n = 12)
2.5 (n = 10)
0.07 (n = 10)
12 (n = 12)

MD (95% CI)

5 ( 10,
5
5.9
0.13
12

1)

( 8, 1)
(2.7,9.0)
( 0.18, 0.08)
( 22, 3)

P-value

g2

0.03

0.18

0.02
0.001
<0.001
0.01

0.22
0.41
0.58
0.24

Univariate GLM comparing between-group primary and secondary covariates used in subsequent statistical analyses in CTL and OA: body mass
index (BMI), brachial artery flow-mediated dilation (FMD), carotid artery intima-media thickness (IMT), systolic blood pressure (SBP). Betweengroup mean differences (MD) with 95% confidence intervals (CI; upper, lower bounds) and values in mean  SD are provided. Bolded P-values indicate significance (P < 0.05).

for reasons that are independent from common cardiovascular/cerebrovascular risk factors. In other words, these
data suggest an independent impact of OA on cerebrovascular function.
Impaired cerebrovascular reactivity in both extracranial
conduit vessel dilation (i.e., internal carotid arteries) and
MCA blood flow indicate impaired dilatory responses to
all levels of the MCA vascular bed. The impaired dilatory
response to hypercapnia, as well as slowed autoregulatory
responses to pressure-dependent stimuli, suggest that dilatory impairments are a generalized feature of OA across
multiple stimuli and cerebrovascular regions, although the
mechanisms are unclear. In younger obese adults (mean
age 37) with BMI > 40 kg/m2, vasomotor reactivity (to a
30-sec apnea test) was lower than age-matched non-obese
adults with BMI < 25 kg/m2 (Rodrıguez-Flores et al.
2014). However, in the current study, BMI did not
account for the between-group cerebrovascular reactivity
(i.e., cerebrovascular cross-sectional area) differences.
White matter lesions (WML) describe a range of neuronal damage, often related to microvascular damage
(Launer 2004; Debette and Markus 2010). Therefore, an
important observation of the present study was the high
volume of WML in the participants with OA; however,
these values are subclinical, as they reside outside of range
volumes observed in patients with small vessel stroke
(Rost et al. 2010) (reported as 3.4–14.7 cm3). Normally,
periventricular white matter lesions are reported to be
greater after total joint replacement (Jonsson et al. 2011),
indicating an effect of OA disease progression on cerebral
microvascular damage. While based on a limited number
of participants, the current data provide the first evidence
indicating subclinical cerebrovascular impairment occurring alongside abnormal (relative to CTL) WML volumes
in patients with OA. Interestingly, these patients also
exhibited lower scores on the cognitive assessments, and

it has been suggested that WMHs have been linked with
neurodegeneration thereby driving cognitive decline
(Rizvi et al. 2017). Generally, hypertension is considered
to be the primary contributor to the development of
white matter hyperintensities, although conflicting evidence exists on whether this results in greater white matter hyperintensities occurrences across the whole brain, or
specific to either periventricular or deep white matter
areas of the brain (Moroni et al. 2018). In the current
study, participants with OA had greater white matter
hyperintensities even after adjusting for the 10-year risk
for CVD/stroke index or SBP (Table 4). Although, it is
important to note that SBP seemed to have an important
role in WML volumes as between-group adjusted mean
differences were lower than the unadjusted mean differences of WML volumes (Table 4).
Cardiovascular and cerebrovascular outcomes in
osteoarthritis are documented, where individuals with
osteoarthritis have a higher risk of experiencing a vascular-related incident than those without osteoarthritis (Calvet et al. 2016; Hall et al. 2016; Hsu et al. 2017). In a
population-based cohort study examining all-cause and
disease specific mortality of adults with either knee or hip
OA (>1000 individuals and >35 years of age), age- and
sex-standardized mortality and hazard ratios were higher
in OA than those without OA, and of particular interest,
excess mortality was pronounced for cardiovascular disease and dementia associated mortality (Nuesch et al.
2011). In the current study, the observed cerebrovascularrelated impairments in the presence of OA were present
even after accounting for risk factors that may have
impacted cerebrovascular control.
Although underlying mechanisms in OA were not the
focus of the current study, potential mechanisms could
include persistent low-grade inflammation, metabolic disturbances, or factors related to limited physical activity
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Figure 1. Unadjusted baseline cross-sectional area (CSA), percent change from baseline in response to hypercapnia (%CSA), and reactivity
(CSA Reactivity; %/mmHg) are shown for the bilateral (right, R; left; L) middle (MCA), posterior (PCA), anterior (ACA) cerebral arteries, and the
internal carotid (ICA) and basilar intracranial arteries across control (CTL) and osteoarthritis (OA) individuals. Values presented as mean  S.D.
Between-group raw mean differences are indicated with * to indicate OA different from CTL after covarying for the primary covariate of 10year risk factor for CVD/stroke.

due to OA symptoms. The comprehensive review by
Zhuo et al. summarizes the inflammatory and oxidative
stress mechanisms shared between OA and metabolic syndrome, and even suggest that metabolic OA should be
considered as a sub-feature of metabolic syndrome (Zhuo
et al. 2012). In our previous narrative review, we provided a synthesis of literature focusing on cerebrovascular
outcomes in osteoarthritis with a proposed shared underlying link of inflammation (Al-Khazraji et al. 2018). There
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are overlapping inflammatory and oxidative mechanisms
at the local and/or systemic level which may contribute to
progression of OA and cerebrovascular dysfunction.
Examples include the lectin-like oxidized low-density
lipoprotein receptor-1 (LOX-1), interleukin-6 (IL-6), and
reactive oxidative species (ROS). LOX-1 is found on the
vascular endothelium, and its activation via increased
superoxide production can lead to vascular thickening
and lipid deposition. Serum cholesterol and lipid
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Figure 2. Unadjusted between-group (control, CTL; osteoarthritis,
OA) cross-sectional area reactivity (from baseline) during
hypercapnia averaged across the nine larger intracranial cerebral
arteries. Both individual participant data (circles) and mean  S.D.
are shown. Between-group raw mean differences are indicated
with * to indicate OA different from CTL, with specific betweengroup differences after primary and secondary covariate analyses
detailed in Table 2.

deposition is greater within the joint during OA (Gkretsi
et al. 2011), and a rodent study using a destabilization of
the medial meniscus as a model (DMM) for OA concluded that LOX-1 activation is required for OA progression (Hashimoto et al. 2016). Systemic plasma levels of
IL-6 are high in OA patients, and rodent studies using
the DMM model for OA determined that IL-6 activation
is involved in catabolic pathways in the joint cartilage
(Latourte et al. 2017). In a 7-year long observational
study conducted in participants with vascular risk factors,
those with higher circulating levels of IL-6 were more
likely to develop dementia (Miwa et al. 2016). Finally,
both cerebrovascular cells and chondrocytes have the ability to produce ROS. Higher levels of ROS in the cerebrovasculature can lead to compromised blood brain
barrier integrity and a higher level of plasma NADPH
oxidase activity in humans has shown to be positively
correlated with greater cartilage degradation (Kim et al.
2015). Although these inflammatory mechanisms were
not reported as simultaneous measures from the cerebrovasculature and the joint in an OA model, there are
enough lines of evidence supporting systemic and local
effects of shared inflammatory mechanisms that may contribute to concurrent degradation of cerebrovascular
health and OA progression.

Cerebrovascular Control in Osteoarthritis

The results of this preliminary study indicate patients
diagnosed with OA can express significant cerebrovascular
dysregulation. Importantly, the impaired cerebrovascular
reactivity to CO2 and pressure-dependent stimuli are suggestive of vascular disease that exists at a subclinical state
and would normally remain undetected in routine followup clinical evaluations. As well, the observed cerebrovascular dysfunction is also accompanied by poorer performance on cognitive assessments. Of note, the MOCA
scores, although lower in the group with OA, were in a
normal range for this age (Nasreddine et al. 2005) but
were explained by WML. Therefore, the current observations provide important insight into epidemiological
studies that indicate high risk for OA patients for cardiovascular disease (Nuesch et al. 2011; Veronese et al.
2016), dementia (Nuesch et al. 2011), and cerebrovascular
events (Hsu et al. 2017). How these events progress in
OA participants remains unknown, but the covariate
analyses suggest that these impairments are not mediated
by known cardiovascular/cerebrovascular risk factors. The
magnitude of cerebrovascular impairment points to a
relationship between OA and cerebrovascular outcomes
that may have critical implications later in life.

Limitations
We relied on pre-existing diagnoses of OA. We did not
perform radiographic examinations or assess the extent of
symptoms. We also did not perform radiographs on the
CTL participants; thus, we cannot confirm participants
did not have radiographic OA (despite self-reported
accounts of no knee symptoms and no OA history). Fully
accounting for co-morbid conditions in OA is difficult,
particularly in an exploratory study with a limited number of participants. For example, we adjusted for the
covariates independently to prevent overfitting (which
may occur when accounting for numerous covariates
(Babyak 2004)). Although our sample size was small, our
effect sizes were considered large and the post-hoc
observed power (SPSS) ranged from 0.7 to 0.99 for our
primary cerebrovascular control variables. Although we
cannot discount the integrative role of comorbidities on
cerebrovascular control, we attempted to adjust for the
role of common and well-established cardiovascular risk
factors as well as a composite risk score. The 10-year
CVD/stroke risk factor is not without its limitations as
more work is required in filling gaps on risk assessment
and outcomes of different racial/ethnic groups across the
age span (Goff et al. 2013). Furthermore, using specific,
rather than composite, secondary covariates yielded differences between our groups. In this study, we attempted to
include data from an equal number of males and females,
and our participants were mostly Caucasian. Finally, the
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Middle cerebral artery flow cerebrovascular reactivity (MCA Flow CVR; %/mmHg), “Global Cerebrovascular Reactivity” (GCR; %/mmHg), and rate of regulation (RoR; s-1) compared between
control (CTL) and osteoarthritis (OA) using univariate GLM with covariates (where 1 - 10-year risk factor for CVD/stroke, 2 – BMI, 3 – FMD, 4 – IMT, and 5 – SBP). Values reported as
mean  SEM. Raw values are reported as mean  SEM (indicated with subscript “u”) and corresponding adjusted mean  SEM (indicated with subscript “a”), and between-group mean differences (MD) with Bonferroni adjusted 95% confidence intervals (CI; upper, lower bounds) are provided. Bolded P-values indicate statistically significant differences between groups
(P < 0.05).
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Table 3. Between-group comparisons of cerebrovascular control with and without covariates.
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Table 4. Cerebral anatomical volumes, cognitive metrics, and index of cerebro-microvascular damage.
CTL
MRI brain volumetric data
Brain volume without ventricles (mL)
Cortical gray matter volume (mL)
Cortical white matter volume (mL)
White matter lesions (mL)
Covariate #1
Covariate #5
Cognitive assessments
MoCA (score out of 30)
Covariate #1
Covariate: white matter lesions
Trail making test A (seconds)
Trail making test B (seconds)

1067
446
445
0.29
0.29
0.55
0.66
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0.50a (n = 12)
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0.6u
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2 (n = 11)
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2

0.77u
0.88 u
0.50 u
0.004u
0.024a

0.005
0.001
0.024
0.357
0.252

0.046a

0.203

2 (1,3)u
2 (1,3)a

0.004u
0.012a

0.32
0.267

1 ( 1,3)a

0.32a

0.059

1 ( 5,8)u
4 ( 25,16)u

0.70u
0.65u

0.007
0.01

1.73 ( 3.44,

0.03)a

Brain anatomy, white matter lesions, and cognitive assessments compared between control (CTL) and osteoarthritis (OA) using univariate GLM
with primary and specific secondary covariate analyses (where 1 - 10-year risk factor for CVD/stroke, and 5 - SBP) for white matter lesions and
MoCA. Raw values are reported as mean  SEM (indicated with subscript “u”) and corresponding adjusted mean  SEM (indicated with subscript “a”), and between-group mean differences (MD) with Bonferroni adjusted 95% confidence intervals (CI; upper, lower bounds) are provided. Bolded P-values indicate statistically significant differences between groups (P < 0.05).

present sample of patients with OA is small and the
extent of disease is unknown.
The reported vascular reactivity and autoregulation
findings may differ depending on the context of the stimulus and analytical methods. Specifically, we reported vascular reactivity to hypercapnia; however, vasoreactivity to
hypocapnia may produce different results than the current findings as reactivity differs between hypercapnia and
hypocapnia in healthy humans (Coverdale et al. 2014; AlKhazraji et al. 2019). Our dynamic autoregulation findings in the MCA may not translate to other regions of
the cerebrovasculature. One such study assessed whether
orthostatic stress affected dynamic cerebral autoregulation
by measuring rate of regulation (via bilateral thigh-cuff
release) at supine and during a 60-degree head-up tilt
maneuver. Although supine dynamic cerebral autoregulation was similar, there was a greater attenuation in the
dynamic cerebral autoregulation response of the vertebral
artery compared to the internal carotid artery during the
head-up tilt (Sato et al. 2012). While our study was conducted under baseline supine conditions, we cannot dismiss the possibility that autoregulation of the posterior
and anterior cerebrovascular beds may behave differently
than the reported MCA values in the OA group.
Despite differences in rate of regulation between
groups, rate of regulation is not a standalone index of
dynamic cerebral autoregulation. Currently, there is a lack
of metric consistency across studies assessing cerebral

autoregulation. Numerous variables used to describe cerebral autoregulation result in different interpretations of
autoregulation and ensuing implications of such findings.
A critical study by Tzeng et al. (2012) assessed the interpretations of cerebral autoregulation by collecting data
from different autoregulation challenges and varying follow-up analytical methods. Their findings highlight a crucial point of consideration when interpreting cerebral
autoregulation studies: conclusions drawn from autoregulation studies require careful interpretation and consideration of metrics used to assess autoregulation. In our
study, we relied on a single metric, rate of regulation, to
provide an index of autoregulation. We also did not
report other important metrics that are useful in understanding dynamic autoregulation when using the sit-to-stand task as an autoregulation challenge, including but
not limited to, time to nadir, relative changes in mean
arterial pressure and MCA blood velocity, time to onset
of regulatory response (Labrecque et al. 2017; Favre and
Serrador 2019; Labrecque et al. 2019). Future studies
should explore and provide reference range for the range
of autoregulatory variables and metavariables, interpret
findings from different context of data collection (sit-to-stand vs. thigh cuff), and acquire responses over the range
of vasoreactivity (hypo-,eu-, and hypercapnia) in individuals with OA.
Therefore, the current data should not be extrapolated
to all cases of OA. Rather, these data point to a
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compelling need for more investigations into the problem
of cerebrovascular impairments in OA.

Summary
This exploratory study is the first to provide preliminary
analyses on cerebrovascular control in patients with knee
OA in the absence of known cardiovascular disease. While
based on a convenience sample of patients, this study
provides evidence for sub-clinical compromise of both
peripheral vascular and cerebrovascular health outcomes,
placing them at risk for cerebrovascular dysfunction and
potential future cerebrovascular events. These observations exist independent of the effects of known cardiovascular/cerebrovascular dysfunction contributing factors.
Future larger-scale studies are required to replicate these
findings and contextualize them in clinical settings where
severity and type of OA, inflammatory biomarkers, and
comorbid risk factors are assessed in tandem with cerebrovascular control.
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